{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:41:36Z","timestamp":1793749296455,"version":"4.6.1"},"reference-count":124,"publisher":"Innovative Healthcare Institute","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment; however, their oral toxicity profile is not well elucidated. This review aimed to investigate the prevalence of oral toxicities including xerostomia, mucositis\/stomatitis, dysgeusia, dysphagia, oral\/oropharyngeal pain, oral infections, angular cheilitis, osteonecrosis, osteomyelitis, and oral mucosal reactions with ICIs. A review protocol was registered with PROSPERO (ID: CRD42023391674). A systematic search of ClinicalTrials.gov was conducted as of April 10, 2022. Studies were selected, assessed, and data extracted using PRISMA guidelines. Oral toxicity data were extracted from study arms using a single immunotherapy drug. Meta-analyses were conducted to summarize prevalence of oral toxicities using random-effects models. Of 750 screened records, 95 trials were included in the meta-analysis with published results. Time between study completion and first publication on ClinicalTrials.gov was 1 to 146 months (mean = 20.3, SD = 18.4). Weighted pooled prevalence was 5% (95% CI: 4\u20136%) for xerostomia, 3% (95% CI: 3\u20134%) for mucositis\/stomatitis, 3% (95% CI: 2\u20133%) for dysgeusia, 2% (95% CI: 1\u20132%) for dysphagia, 3% (95% CI: 2\u20134%) for oropharyngeal\/oral pain, 2% (95% CI: 1\u20133%) for oral candidiasis, and 2% (95% CI: 0\u20134%) for angular cheilitis. Subgroup differences based on ICI drugs were minimal. No trials reported lichenoid or pemphigoid mucosal reactions. Meta-analysis results revealed low prevalence of oral toxicities with ICIs; however, data reporting was limited and inconsistent. Limitations of study dataset reveal a significant need for systematic collection of oral morbidity data as well as improved consistency and compliance of reporting results on ClinicalTrials.gov.<\/jats:p>","DOI":"10.36401\/jipo-23-14","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T07:07:32Z","timestamp":1699513652000},"page":"24-40","source":"Crossref","is-referenced-by-count":26,"title":["Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials"],"prefix":"10.36401","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6755-6535","authenticated-orcid":true,"given":"Akanksha","family":"Srivastava","sequence":"first","affiliation":[{"name":"1 Craniofacial Center, Division of Plastic Surgery, Department of Surgery, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela M.","family":"Nogueras-Gonzalez","sequence":"additional","affiliation":[{"name":"2 Department of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Geng","sequence":"additional","affiliation":[{"name":"3 Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasdev","family":"Singh","sequence":"additional","affiliation":[{"name":"4 DMD-1 student, Midwestern University, Downers Grove, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Myers","sequence":"additional","affiliation":[{"name":"5 Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yisheng","family":"Li","sequence":"additional","affiliation":[{"name":"2 Department of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Chambers","sequence":"additional","affiliation":[{"name":"6 Section of Oral Oncology and Maxillofacial Prosthodontics, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2024,2,5]]},"reference":[{"key":"2024020423515368300_i2590-017X-7-1-24-b01","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC)","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b02","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2024020423515368300_i2590-017X-7-1-24-b03","doi-asserted-by":"crossref","first-page":"e223461","DOI":"10.1001\/jamanetworkopen.2022.3461","article-title":"Immune-related adverse events after immune checkpoint inhibitors for melanoma among older adults","volume":"5","author":"Schonfeld","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024020423515368300_i2590-017X-7-1-24-b04","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/odi.13964","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2022","journal-title":"Oral Dis"},{"key":"2024020423515368300_i2590-017X-7-1-24-b05","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/1346-8138.14205","article-title":"Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: a report of two cases and published work review","volume":"45","author":"Obara","year":"2018","journal-title":"J Dermatol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b06","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ijom.2018.07.025","article-title":"Drug-induced oral lichenoid reaction during nivolumab therapy","volume":"48","author":"Enomoto","year":"2019","journal-title":"Int J Oral Maxillofac Surg"},{"key":"2024020423515368300_i2590-017X-7-1-24-b07","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b08","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.oooo.2020.06.014","article-title":"Severe oral erosive lichenoid reaction to pembrolizumab therapy","volume":"130","author":"Bhattacharyya","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b09","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2024020423515368300_i2590-017X-7-1-24-b12","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1111\/jdv.16036","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"Fassler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fmed.2018.00268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud","year":"2019","journal-title":"Eur J Cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b16","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/1078155218791314","article-title":"Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy","volume":"25","author":"Hwang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2024020423515368300_i2590-017X-7-1-24-b17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/1078155219890659","article-title":"Toxic epidermal necrolysis associated with pembrolizumab","volume":"26","author":"Cai","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"2024020423515368300_i2590-017X-7-1-24-b18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/apnr.2002.34181","article-title":"Popping the (PICO) question in research and evidence-based practice","volume":"15","author":"Stone","year":"2002","journal-title":"Appl Nurs Res"},{"key":"2024020423515368300_i2590-017X-7-1-24-b19","article-title":"ClinicalTrials.gov protocol registration data element definitions for interventional and observational studies"},{"key":"2024020423515368300_i2590-017X-7-1-24-b20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bmj.38356.424606.8F","article-title":"Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors","volume":"330","author":"Chan","year":"2005","journal-title":"BMJ"},{"key":"2024020423515368300_i2590-017X-7-1-24-b21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/biostatistics\/2.4.463","article-title":"On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions","volume":"2","author":"Greenland","year":"2001","journal-title":"Biostatistics"},{"key":"2024020423515368300_i2590-017X-7-1-24-b22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"metan: fixed- and random-effects meta-analysis","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J"},{"key":"2024020423515368300_i2590-017X-7-1-24-b23","doi-asserted-by":"crossref","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","article-title":"Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study","volume":"6","author":"Cheng","year":"2016","journal-title":"BMJ Open"},{"key":"2024020423515368300_i2590-017X-7-1-24-b24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2024020423515368300_i2590-017X-7-1-24-b25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2024020423515368300_i2590-017X-7-1-24-b26","article-title":"Study of pembrolizumab (MK-3475) monotherapy in advanced solid tumors and pembrolizumab combination therapy in advanced non-small cell lung cancer\/extensive-disease small cell lung cancer (MK-3475\u2013011\/KEYNOTE-011)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b27","article-title":"Study to evaluate the safety and efficacy of two different dosing schedules of pembrolizumab (MK-3475) compared to ipilimumab in participants with advanced melanoma (MK-3475\u2013006\/KEYNOTE-006)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b28","article-title":"Study of pembrolizumab (MK-3475) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990\/MK-3475\u2013001\/KEYNOTE-001)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b29","article-title":"Study of pembrolizumab (MK-3475) versus chemotherapy in participants with advanced melanoma (MK-3475\u2013002\/P08719\/KEYNOTE-002)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b30","article-title":"Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475\u2013012\/KEYNOTE-012)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b31","article-title":"Study of two doses of pembrolizumab (MK-3475) versus docetaxel in previously treated participants with non-small cell lung cancer (MK-3475\u2013010\/KEYNOTE-010)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b32","article-title":"A trial of pembrolizumab (MK-3475) in participants with blood cancers (MK-3475\u2013013\/KEYNOTE-013)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b33","article-title":"Study of pembrolizumab (MK-3475) in participants with advanced non-small cell lung cancer (MK-3475\u2013025\/KEYNOTE-025)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b34","article-title":"Anti-PD-1 monoclonal antibody in advanced, trastuzumab-resistant, HER2-positive breast cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b35","article-title":"Study of pembrolizumab (MK-3475) compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (MK-3475\u2013024\/KEYNOTE-024)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b36","article-title":"Study of pembrolizumab (MK-3475) in participants with advanced melanoma (MK-3475\u2013041\/KEYNOTE-041)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b37","article-title":"Study of MK-3475 (pembrolizumab) in recurrent or metastatic head and neck squamous cell carcinoma after treatment with platinum-based and cetuximab therapy (MK-3475\u2013055\/KEYNOTE-055)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b38","article-title":"A Study of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for participants with advanced urothelial cancer (MK-3475\u2013045\/KEYNOTE-045)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b39","article-title":"SARC028: A phase II study of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas"},{"key":"2024020423515368300_i2590-017X-7-1-24-b40","article-title":"Neoadjuvant pembrolizumab for unresectable stage III and unresectable stage IV melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b41","article-title":"Phase 2 multi-center study of anti-PD-1 during lymphopenic state after HDT\/ASCT for multiple myeloma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b42","article-title":"Pembrolizumab +\/\u2212 bevacizumab for recurrent GBM"},{"key":"2024020423515368300_i2590-017X-7-1-24-b43","article-title":"Study of the combination of ACP-196 and pembrolizumab in subjects with platinum resistant urothelial bladder cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b44","article-title":"A study of pembrolizumab (MK-3475) versus paclitaxel for participants with advanced gastric\/gastroesophageal junction adenocarcinoma that progressed after therapy with platinum and fluoropyrimidine (MK-3475\u2013061\/KEYNOTE-061)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b45","article-title":"Study of pembrolizumab (MK-3475) monotherapy for metastatic triple-negative breast cancer (MK-3475\u2013086\/KEYNOTE-086)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b46","article-title":"Pembrolizumab alone and in combination with acalabrutinib (ACP-196) in subjects with advanced non-small cell lung cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b47","article-title":"Study of the combination of acalabrutinib (ACP-196) and pembrolizumab in advanced head and neck squamous cell carcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b48","article-title":"Pembrolizumab and cryosurgery in treating patients with newly diagnosed, oligo-metastatic prostate cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b49","article-title":"Study of single agent pembrolizumab (MK-3475) versus single agent chemotherapy for metastatic triple negative breast cancer (MK-3475\u2013119\/KEYNOTE-119)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b50","article-title":"Study of pembrolizumab (MK-3475) in participants with relapsed or refractory primary mediastinal large B-cell lymphoma or relapsed or refractory Richter syndrome (MK-3475\u2013170\/KEYNOTE-170)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b51","article-title":"Pembrolizumab in patients failing to respond to or relapsing after CAR T cell therapy for relapsed or refractory lymphomas"},{"key":"2024020423515368300_i2590-017X-7-1-24-b52","article-title":"Pembrolizumab (Keytruda) in advanced hepatocellular carcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b53","article-title":"Efficacy and safety study of pembrolizumab (MK-3475) in participants with advanced recurrent ovarian cancer (MK-3475\u2013100\/KEYNOTE-100)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b54","article-title":"Pembrolizumab with or without vismodegib in treating metastatic or unresectable basal cell skin cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b55","article-title":"Study of pembrolizumab (MK-3475) vs. best supportive care in participants with previously systemically treated advanced hepatocellular carcinoma (MK-3475\u2013240\/KEYNOTE-240)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b56","article-title":"A phase II study of pembrolizumab as post-remission treatment of patients \u2265 60 with AML"},{"key":"2024020423515368300_i2590-017X-7-1-24-b57","article-title":"A phase 3 study of pembrolizumab + epacadostat or placebo in subjects with unresectable or metastatic melanoma (Keynote-252 ECHO-301)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b58","article-title":"A study of pembrolizumab in patients with neuroendocrine tumors"},{"key":"2024020423515368300_i2590-017X-7-1-24-b59","article-title":"Pembrolizumab in recurrent or metastatic medullary thyroid cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b60","article-title":"A study of cobimetinib plus atezolizumab versus pembrolizumab in participants with previously untreated advanced BRAFv600 wild-type melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b61","article-title":"Pembrolizumab plus epacadostat vs pembrolizumab plus placebo in metastatic non-small cell lung cancer (KEYNOTE-654\u201305\/ECHO-305\u201305)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b62","article-title":"Pembrolizumab in combination with epacadostat or placebo in cisplatin-ineligible urothelial carcinoma (KEYNOTE-672\/ECHO-307)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b63","article-title":"Pembrolizumab + epacadostat vs pembrolizumab + placebo in recurrent or progressive metastatic urothelial carcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b64","article-title":"A study of MDX-1106 in patients with selected refractory or relapsed malignancies"},{"key":"2024020423515368300_i2590-017X-7-1-24-b65","article-title":"Phase I biomarker study (BMS-936558)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b66","article-title":"PH 1 biomarker study of nivolumab and ipilimumab and nivolumab in combination with ipilimumab in advanced melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b67","article-title":"Study of nivolumab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have either failed or are not eligible for autologous stem cell transplant (CheckMate 139)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b68","article-title":"A phase 1\/2, open-label study to evaluate the safety and antitumor activity of MEDI0680 (AMP-514) in combination with durvalumab versus nivolumab monotherapy in participants with select advanced malignancies"},{"key":"2024020423515368300_i2590-017X-7-1-24-b69","article-title":"A single-arm, open-label, multicenter clinical trial with nivolumab (BMS-936558) for subjects with histologically confirmed stage III (unresectable) or stage IV melanoma progressing post prior treatment containing an anti-CTLA4 monoclonal antibody (CheckMate 172)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b70","article-title":"Nivolumab in treating patients with recurrent and\/or metastatic nasopharyngeal cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b71","article-title":"An open-label, multicenter clinical trial with nivolumab (BMS-936558) monotherapy in subjects with advanced or metastatic squamous cell (Sq) non-small cell lung cancer (NSCLC) who have received at least one prior systemic regimen for the treatment of stage IIIb\/IV SqNSCLC"},{"key":"2024020423515368300_i2590-017X-7-1-24-b72","article-title":"A study of nivolumab in advanced non-small cell lung cancer (NSCLC)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b73","article-title":"Nivolumab and yttrium Y 90 glass microspheres in treating patients with advanced liver cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b74","article-title":"A Study of nivolumab in relapsed\/refractory primary central nervous system lymphoma (PCNSL) and relapsed\/refractory primary testicular lymphoma (PTL)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b75","article-title":"Study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in adults with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b76","article-title":"An investigational immuno-therapy study of nivolumab combined with ipilimumab compared to nivolumab by itself after complete surgical removal of stage IIIb\/c\/d or stage IV melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b77","article-title":"An investigational immuno-therapy study of BMS-986205 combined with nivolumab, compared to nivolumab by itself, in patients with advanced melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b78","article-title":"MDX-010 antibody, MDX-1379 melanoma vaccine, or MDX-010\/MDX-1379 combination treatment for patients with unresectable or metastatic melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b79","article-title":"MDX-010 in treating patients with stage IV pancreatic cancer that cannot be removed by surgery"},{"key":"2024020423515368300_i2590-017X-7-1-24-b80","article-title":"A companion study for patients enrolled in prior\/parent ipilimumab studies"},{"key":"2024020423515368300_i2590-017X-7-1-24-b81","article-title":"Study of MDX-010 in patients with metastatic hormone-refractory prostate cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b82","article-title":"Evaluation of tumor response to ipilimumab in the treatment of melanoma with brain metastases"},{"key":"2024020423515368300_i2590-017X-7-1-24-b83","article-title":"Efficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b84","article-title":"Drug-drug interaction - 3 arm - carboplatin\/paclitaxel, dacarbazine"},{"key":"2024020423515368300_i2590-017X-7-1-24-b85","article-title":"Comparison of ipilimumab manufactured by 2 different processes in participants with advanced melanoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b86","article-title":"Phase 3 study of immunotherapy to treat advanced prostate cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b87","article-title":"Study of nivolumab (BMS-936558) in combination with gemcitabine\/cisplatin, pemetrexed\/cisplatin, carboplatin\/paclitaxel, bevacizumab maintenance, erlotinib, ipilimumab or as monotherapy in subjects with stage IIIB\/IV non-small cell lung cancer (NSCLC) (CheckMate 012)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b88","article-title":"An efficacy study in gastric and gastroesophageal junction cancer comparing ipilimumab versus standard of care immediately following first line chemotherapy"},{"key":"2024020423515368300_i2590-017X-7-1-24-b89","article-title":"Phase II study of ipilimumab monotherapy in recurrent platinum-sensitive ovarian cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b90","article-title":"Evaluation of circulating T cells and tumor infiltrating lymphocytes (TILs) during after pre-surgery chemotherapy in non-small cell lung cancer (NSCLC)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b91","article-title":"Phase 2 study of ipilimumab in Japanese advanced melanoma patients"},{"key":"2024020423515368300_i2590-017X-7-1-24-b92","article-title":"Nab-paclitaxel and bevacizumab or ipilimumab as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery"},{"key":"2024020423515368300_i2590-017X-7-1-24-b93","article-title":"Ipilimumab vs ipilimumab plus nivolumab in patients with stage III-IV melanoma who have progressed or relapsed on PD-1 inhibitor therapy"},{"key":"2024020423515368300_i2590-017X-7-1-24-b94","article-title":"A phase 1\/2 study to evaluate MEDI4736"},{"key":"2024020423515368300_i2590-017X-7-1-24-b95","article-title":"Phase II study of MEDI4736 monotherapy in treatment of recurrent or metastatic squamous cell carcinoma of the head and neck"},{"key":"2024020423515368300_i2590-017X-7-1-24-b96","article-title":"Evaluate the efficacy of MEDI4736 in immunological subsets of advanced colorectal cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b97","article-title":"Phase II study of MEDI4736, tremelimumab, and MEDI4736 in combination w\/tremelimumab squamous cell carcinoma of the head and neck"},{"key":"2024020423515368300_i2590-017X-7-1-24-b98","article-title":"Phase 2 study of durvalumab (MEDI4736) in patients with glioblastoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b99","article-title":"A phase 1b\/2 study of MEDI4736 with tremelimumab, MEDI4736 or tremelimumab monotherapy in gastric or GEJ adenocarcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b100","article-title":"Study of MEDI4736 monotherapy and in combination with tremelimumab versus standard of care therapy in patients with head and neck cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b101","article-title":"Phase III open label study of MEDI 4736 with\/without tremelimumab versus standard of care (SOC) in recurrent\/metastatic head and neck cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b102","article-title":"Phase II study of MEDI4736 monotherapy or in combinations with tremelimumab in metastatic pancreatic ductal carcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b103","article-title":"A study of atezolizumab in participants with programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic non-small cell lung cancer (NSCLC) FIR"},{"key":"2024020423515368300_i2590-017X-7-1-24-b104","article-title":"A randomized phase 2 study of atezolizumab (an engineered anti-PDL1 antibody) compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum therapy - \u201cPOPLAR.\u201d"},{"key":"2024020423515368300_i2590-017X-7-1-24-b105","article-title":"A Study of atezolizumab (an engineered anti-programmed death-ligand 1 PD-L1 antibody) as monotherapy or in combination with bevacizumab (Avastin\u00ae) compared to sunitinib (Sutent\u00ae) in participants with untreated advanced renal cell carcinoma"},{"key":"2024020423515368300_i2590-017X-7-1-24-b106","article-title":"A study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed platinum-containing therapy"},{"key":"2024020423515368300_i2590-017X-7-1-24-b107","article-title":"A study of atezolizumab in participants with programmed death-ligand 1 (PD-L1) positive locally advanced or metastatic non-small cell lung cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b108","article-title":"A study of atezolizumab compared with chemotherapy in participants with locally advanced or metastatic urothelial bladder cancer IMvigor211"},{"key":"2024020423515368300_i2590-017X-7-1-24-b109","article-title":"A study of atezolizumab in advanced solid tumors"},{"key":"2024020423515368300_i2590-017X-7-1-24-b110","article-title":"A study to investigate efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy versus regorafenib in participants with metastatic colorectal adenocarcinoma (COTEZO IMblaze370)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b111","article-title":"A study of atezolizumab as first-line monotherapy for advanced or metastatic non-small cell lung cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b112","article-title":"A study of daratumumab in combination with atezolizumab compared with atezolizumab alone in participants with previously treated advanced or metastatic non-small cell lung cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b113","article-title":"Avelumab in metastatic or locally advanced solid tumors (JAVELIN Solid Tumor JPN)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b114","article-title":"Avelumab in non-small cell lung cancer (JAVELIN Lung 200)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b115","article-title":"Avelumab in first-line maintenance gastric cancer (JAVELIN Gastric 100)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b116","article-title":"Avelumab in third-line gastric cancer (JAVELIN Gastric 300)"},{"key":"2024020423515368300_i2590-017X-7-1-24-b117","article-title":"Avelumab for people with recurrent respiratory papillomatosis"},{"key":"2024020423515368300_i2590-017X-7-1-24-b118","article-title":"PD-L1 inhibition as checkpoint immunotherapy for neuroendocrine phenotype prostate cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b119","article-title":"Hormone therapy and ipilimumab in treating patients with advanced prostate cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b120","article-title":"Phase Ib\/II study of carboplatin + M6620 + avelumab in PARPi-resistant ovarian cancer"},{"key":"2024020423515368300_i2590-017X-7-1-24-b121","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000487085","article-title":"Burden of oral mucositis: a systematic review and implications for future research","volume":"41","author":"Berger","year":"2018","journal-title":"Oncol Res Treat"},{"key":"2024020423515368300_i2590-017X-7-1-24-b122","doi-asserted-by":"crossref","first-page":"e77086","DOI":"10.1371\/journal.pone.0077086","article-title":"The state of infectious diseases clinical trials: a systematic review of ClinicalTrials.gov","volume":"8","author":"Goswami","year":"2013","journal-title":"PLoS One"},{"key":"2024020423515368300_i2590-017X-7-1-24-b123","doi-asserted-by":"crossref","first-page":"224","DOI":"10.11604\/pamj.2018.29.224.12683","article-title":"A comparison of five international clinical trial registers with the South African register for access to information and usability","volume":"29","author":"Sibanda","year":"2018","journal-title":"Pan Afr Med J"},{"key":"2024020423515368300_i2590-017X-7-1-24-b124","doi-asserted-by":"crossref","first-page":"k1452","DOI":"10.1136\/bmj.k1452","article-title":"How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider","volume":"361","author":"Tse","year":"2018","journal-title":"BMJ"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/1\/24\/3324506\/i2590-017x-7-1-24.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/7\/1\/24\/3324506\/i2590-017x-7-1-24.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:44Z","timestamp":1765475324000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/7\/1\/article-p24.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-23-14","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}